A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

The Congressional Budget Office estimates the package would add $2.4 trillion to the national deficit over a decade and leave ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

While citing overwhelming barriers patients in rural areas face when accessing care, providers noted the potential of telehealth to improve access in a survey.

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, ...

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

In the US, individuals die during pregnancy and the postpartum period at a greater and increasing rate than in any other high ...

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations ...